Public list: Pharma Startups (4733) Cancer Therapeutics (1136)

OnKure is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that include selective inhibitors of histone deacetylases (HDACs). In preclinical models of both hematological and solid tumor cancers, the company's lead candidate, ONK102, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies.

OnKure is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that include selective inhibitors of histone deacetylases (HDACs). In preclinical models of both hematological and solid tumor cancers, the company...Show all

Company (Alive / Active)

Phone: 720-323-9110

Fax:

1105 Spruce Street

Boulder, 80302
Colorado, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
OnKure $9M Feb 8, 2018

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related OnKure Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Undisclosed InvestorsOtherConvertible Note, Unattributed - II, Unattributed
Delian CapitalVenture CapitalBeijing, Beijing, ChinaSeries A
Lapam CapitalVenture CapitalBeijing, Beijing, ChinaSeries A
See all 3 investors

Board Members

There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Process for the preparation of cyclic depsipeptides May 27, 2015 Application